Loading stock data…
Cardinal Health, Inc. (CAH)
$228.03+2.05 (+0.91%)
Market ClosedLast close Jul 24
Cardinal Health, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cardinal Health, Inc. in the Healthcare sector is trading at $228.03 with a market capitalization of $45.9B. Wall Street consensus targets $252.40 (15 analysts), implying a +10.7% move over the next 12 months. The stock is currently near its 52-week high of $243.21, remaining 10.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +10.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $60.94B↓ | $65.63B↑ | $64.01B↑ | $60.16B↑ | $54.88B |
| Gross Profit | $2.50B↑ | $2.40B↑ | $2.32B↑ | $2.20B↑ | $2.12B |
| Operating Income | $842.00M↑ | $763.00M↑ | $754.00M↑ | $585.00M↓ | $656.00M |
| Net Income | $399.00M↓ | $467.00M↑ | $450.00M↑ | $239.00M↓ | $506.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company prov...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$45.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.90
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.89%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.91%
Volume
Today's trading volume
1.18M
Recent News
Ecolab Gears Up to Report Q2 Results: How to Play the Stock?
ECL's Q2 results are likely to benefit from strong growth engines and pricing gains, but elevated input costs may test margins and earnings momentum.
Can GE HealthCare Sustain Growth in Q2 Amid Persistent Cost Headwinds?
GE HealthCare heads into Q2 earnings season with solid revenue drivers, but inflation and tariff costs may keep margins under pressure before an expected second-half recovery.
Will Baxter's Q2 Results Continue to Reflect Operational Headwinds?
BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs
RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.